Ultragenyx Pharmaceutical Inc. Reports Director and Officer Changes
Ticker: RARE · Form: 8-K · Filed: May 19, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | May 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Ultragenyx filed an 8-K on May 15th detailing director/officer changes and votes.
AI Summary
Ultragenyx Pharmaceutical Inc. filed an 8-K on May 19, 2025, reporting events that occurred on May 15, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors or officers can indicate internal shifts that may affect company strategy or performance.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- May 15, 2025 (date) — Date of earliest event reported
- May 19, 2025 (date) — Date of report
FAQ
What specific events are detailed regarding director or officer changes?
The filing indicates the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers.
What other significant corporate actions are reported in this 8-K?
The filing also reports the submission of matters to a vote of security holders and includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported occurred on May 15, 2025.
What is the exact name of the company filing this report?
The exact name of the Registrant is Ultragenyx Pharmaceutical Inc.
What is the principal executive office address of Ultragenyx Pharmaceutical Inc.?
The address of the Principal Executive Offices is 60 Leveroni Court, Novato, California, 94949.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Ultragenyx Pharmaceutical Inc. (RARE).